GenFleet and Merck KGaA Partner on European Clinical Study for KRAS G12C Inhibitor
China-based GenFleet Therapeutics Inc. has announced a European multi-center clinical study and drug supply agreement...
Clinical trial approval / initiation
Henlius Biotech Initiates Phase I Trial for HLX60 in Australia
Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the first subject dosed in a Phase...
ImmuneOnco’s IMM2520 Receives FDA Clinical Trial Approval
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced receiving clinical trial approval from the US FDA for...
Asieris Pharmaceuticals Enrolls First Patient in Phase II Study for APL-1202
China-based Asieris Pharmaceuticals (SHA: 688176) announced the first patient enrollment in a Phase II clinical...
Jiangsu Yahong Administers First Dose of Hexvix in Hainan Pilot Zone
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) announced the first...
Yantai Dongcheng Pharma Acquires Rights to 18F-APN-1607 from Aprinoia Therapeutics
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) announced the plan to acquire the...
MicuRx Pharmaceuticals Gains Clinical Trial Approvals for MRX-4 in Europe
Sino-US firm MicuRx Pharmaceuticals Inc. announced receiving clinical trial approvals in France, Greece, Hungary, Italy,...
Hybio Receives Ethical Approval for HY3000 COVID-19 Nasal Spray Phase II Study
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced receiving ethical approval for a Phase II...
Henlius Biotech Doses First Patient in Phase I Study for HLX60 in China
Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing of a Phase I...
Lynk Pharmaceuticals Doses First Patient in Phase II Study for LNK01003
China-based Lynk Pharmaceuticals (Hangzhou) Co., Ltd announced first patient dosing in a Phase II clinical...
Innovent Biologics Doses First Volunteer in Orismilast Phase I Study
China-based Innovent Biologics Inc., (HKG: 1801) and Denmark-based partner Union Therapeutics A/S revealed that a...
Daiichi Sankyo Doses First Patient in Global Phase III TROPION-Lung08 Study
Japan-based Daiichi Sankyo Inc. (TYO: 4568) announced the first patient dosed in the global multi-center...
Peijia Medical Enrolls First Patient in GeminiOne TEER System Study
China’s Peijia Medical Ltd (HKG: 9996) announced first patient enrollment in a multi-center clinical study...
Pyxis Oncology Receives FDA Approval for Biosion’s PYX-106 Clinical Trials
China-based Biosion, Inc’s US partner Pyxis Oncology, Inc. (NASDAQ: PYXS) announced receiving clinical trial approval...
ImmuneOnco Initiates Phase II Clinical Study for CD47 Antibody IMM01
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has announced the initiation of a Phase II clinical study...
Double-Crane Pharma Gains NMPA Approval for COVID-19 Drug CX2101A Clinical Trials
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) has announced receiving clinical trial approval from...
Youcare’s YKYYO17 Aerosol Inhalation Agent Approved for COVID-19 Clinical Study
China-based Youcare Pharmaceutical Group’s YKYYO17 aerosol inhalation agent, a broad-spectrum coronavirus membrane fusion inhibitor polypeptide...
Ascletis Pharma Completes Enrollment for ASC40 Phase II Acne Study
China-based Ascletis Pharma Inc. (HKG: 1672) announced the completion of enrollment of 180 patients in...
Luye Pharma Initiates Phase II Study for LY 03014 in China
China-based Luye Pharma Group (HKG: 2186) has announced the first patient dosing in a Phase...
Henlius Completes First Dosing in Head-to-Head Study of PD-1 Inhibitor HanSiZhuang
Shanghai Henlius Biotech (HKG: 2696) has announced the completion of the first subject dosing in...